CN101695507A - Medicament for treating diabetes - Google Patents
Medicament for treating diabetes Download PDFInfo
- Publication number
- CN101695507A CN101695507A CN200910236067A CN200910236067A CN101695507A CN 101695507 A CN101695507 A CN 101695507A CN 200910236067 A CN200910236067 A CN 200910236067A CN 200910236067 A CN200910236067 A CN 200910236067A CN 101695507 A CN101695507 A CN 101695507A
- Authority
- CN
- China
- Prior art keywords
- gypsum fibrosum
- medicine
- diabetes
- scorpion
- water extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention discloses a medicament for treating diabetes. Active components of the medicament for treating the diabetes are prepared from the following raw materials in part by weight: 0.5 to 2 parts of scorpion and 8 to 12 parts of gypsum. The medicament is a natural and simple Chinese medicinal compound preparation, which combines animal and mineral medicaments in traditional Chinese medicaments for preventing and treating the diabetes progressively increased for the first time. The medicament has the effects of strengthening insulin sensitivity, reducing fasting and postprandial blood glucose, regulating lipid disturbance caused by the diabetes and the like, and has the action mechanism of mainly promoting the recovery of pancreas islet function. The scorpion dosage in the medicament is the common safe dosage, and obvious toxic or side effects are not found in the usability process. The medicament is unique in curative effect, clear in mechanism and simple in process and is suitable for industrialization and international markets.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of diabetes.
Background technology
Diabetes are diseases of a kind of chronic dysbolismus, have become the 3rd main noninfectious after cardiovascular and cerebrovascular disease and tumor, and sickness rate accounts for 5% of total population number.Diabetes mainly are divided into type 1 diabetes and type 2 diabetes mellitus, and wherein type 2 diabetes mellitus accounts for more than 90%.Type 1 diabetes mainly shows as the islet function defective, and insulin level reduces or lacks, and serious hyperglycemia occurs, lose weight, and glucose in urine, appetite increases, and needs supplementation with insulin just can keep euglycemia, is called insulin dependent diabetes mellitus (IDDM) again.Type 2 diabetes mellitus mainly shows as insulin resistant in early days, and insulin level raises, constant or reduction, and insulin lacks relatively, multiple symptom such as blood sugar increasing.Late period, type 2 diabetes mellitus patient islet function can not be compensatory, shows as insulin and definitely lack, and also need supplementation with insulin just can keep euglycemia this moment.Therefore be not difficult to find that no matter type 1 diabetes or type 2 diabetes mellitus, the absolute shortage will appear in final insulin, having the medicine that promotes islet function to recover might really deal with problems.But in the medicine of listing, the medicine that clearly has this function lacks very much at present.
Sulfonylureas promotes insulin to discharge, but life-time service can cause the islet cells insulin to discharge obstacle.Biguanides promotes organism metabolism, blood sugar lowering, but can not reverse or delay the development of diabetes.The medicine that suppresses alpha-glucosidase only can suppress post-prandial glycemia.Thiophene Zo alkane two ketone drug mains will strengthen the sensitivity of insulin, must be based on insulin.The analog of recent findings glucagon kind polypeptide-1 (GLP-1) or agonist can promote the release of insulin, DPP IV (DDPIV) but the degraded of inhibitor GLP-1, promote the release of insulin, but the irreversible disappearance of islet function will make its ineffective basis.The advanced diabetes drug main will rely on insulinize, but there are shortcomings such as administering mode inconvenience in insulinize, and can not deal with problems basic.Therefore promoting islet function to recover or delay medicine that its function loses is only and solves the key that diabetes worsen progress.Add said medicine and have various side effect, so market still needs to have the antidiabetic thing of new purposes and mechanism.
Summary of the invention
The purpose of this invention is to provide a kind of medicine for the treatment of diabetes.
The medicine of treatment diabetes provided by the invention, its active ingredient is made for raw material by the Scorpio (crude drug) of 0.5-2 weight portion and the Gypsum Fibrosum (crude drug) of 8-12 weight portion.
The active ingredient of described medicine can be that raw material is made by the Scorpio of 1 weight portion and the Gypsum Fibrosum of 10 weight portions specifically.
The active component of described medicine specifically can be the mixture of scorpion and Gypsum Fibrosum water extract.
The preparation method of described Gypsum Fibrosum water extract can be: add entry in the Gypsum Fibrosum, 90-100 ℃ water-bath 0.5-3 hour, collect extracting solution, be Gypsum Fibrosum water extract (Gypsum Fibrosum water extract net weight after drying accounts for the 5%-15% of former Gypsum Fibrosum crude drug weight).
The preparation method of described Gypsum Fibrosum water extract more specifically can be: the distilled water that adds 5 times of weight in the Gypsum Fibrosum, 95 ℃ of water-baths 1 hour, filter (available Cotton Gossypii or filtered through gauze), obtain the Gypsum Fibrosum water extract (the Gypsum Fibrosum water extract after drying net weight account for former Gypsum Fibrosum crude drug weight about 10%).The preparation method of described scorpion can be: with 60 ℃ of dryings of Scorpio 24 hours, pulverize, cross 100 mesh sieves, obtain scorpion.With the described scorpion that adopts method for preparing to obtain and described Gypsum Fibrosum water extract mixed, be the active component of described medicine by 1g: 50ml.
Scorpio Gypsum Fibrosum compound recipe decocting preparation can directly use, and uses after also can being dried to solid, also can be dried to be made into various pharmaceutical formulations with other pharmaceutic adjuvant behind the solid and to use.The dosage form of described medicine can be decoction, electuary, powder or pill.Described medicine can be soft capsule, granule or oral liquid.
The present invention also protects the preparation method of the medicine of described treatment diabetes, comprises the steps: the scorpion of 0.5-2 weight portion and the water extract of 8-12 weight portion Gypsum Fibrosum are mixed the medicine of the diabetes that obtain medical treatment.
The preparation method of described Gypsum Fibrosum water extract can be: add entry in the Gypsum Fibrosum, 90-100 ℃ water-bath 0.5-3 hour, collect extracting solution, be Gypsum Fibrosum water extract (Gypsum Fibrosum water extract net weight after drying accounts for the 5%-15% of former Gypsum Fibrosum crude drug weight).
The preparation method of described Gypsum Fibrosum water extract more specifically can be: the distilled water that adds 5 times of weight in the Gypsum Fibrosum, 95 ℃ of water-baths 1 hour, filter (available Cotton Gossypii or filtered through gauze), obtain the Gypsum Fibrosum water extract (the Gypsum Fibrosum water extract after drying net weight account for former Gypsum Fibrosum crude drug weight about 10%).The preparation method of described scorpion can be: with 60 ℃ of dryings of Scorpio 24 hours, pulverize, cross 100 mesh sieves, obtain scorpion.With the described scorpion that adopts method for preparing to obtain and the described Gypsum Fibrosum water extract mixed by 1g: 50ml, the mixture that obtains is the active component of described medicine.
The using dosage of medicine mice of the present invention is: (water extract with 350mg scorpion and 3.5g Gypsum Fibrosum mixes the medicine that obtains)/kg/day; Application method is oral; Scorpio dosage forms according to Scorpio crude drug people's using dosage conversion: 1.5g * (35/3)/50kg=350mg/ kg/day; Gypsum Fibrosum dosage forms according to Gypsum Fibrosum crude drug people's using dosage conversion: 15g * (35/3)/50kg=3.50g/ kg/day.Medicine people's of the present invention every day, clinical dosage on probation recommended to be reduced to (water extract with 1.5g scorpion and 15g Gypsum Fibrosum mixes the medicine that obtains)/sky; Application method is oral.
Medicine of the present invention, can liquid, the form of dry powder or extractum exists, also can be prepared into various dosage forms such as capsule, tablet, injection, pill, granule, powder, can be used for prevention and treatment diabetes and complication thereof separately or with the other medicines combination with various conventional adjuvants with health care or medicinal efficacy.Medicine provided by the invention can improve insulin sensitivity, reduces on an empty stomach and complication such as post-prandial glycemia, adjusting diabetes blood fat disorder, and mechanism of action relates to the promotion islet cell function and recovers.
Medicine provided by the invention is a kind of natural, simple compound Chinese medicinal preparation, and this is first animal in the Chinese medicine and mineral drug to be joined together to be used at present the prevention and the treatment of the diabetes of increase day by day.This medicine has strengthens the effects such as lipid disorders that insulin sensitivity, reduction empty stomach and post-prandial glycemia, adjusting diabetes cause, and mechanism of action is mainly and promotes islet function to recover.Scorpio dosage is safe dose commonly used in this medicine, and the process of share is not found obvious toxic-side effects, special effect, and mechanism is clear, and technology is very simple, is fit to industrialization and moves towards the international market.
Description of drawings
Fig. 1 is that the mice fasting glucose is in the variation of 0-6 in week.
Fig. 2 is the variation of mice serum insulin and pancreatic tissue insulin level.
Fig. 3 tests HE coloration result (400 times of amplifications) behind the medicine 5 week back pancreatic tissue pathological sections for mice.
Fig. 4 tests the expression of 5 week of medicine back pancreatic tissue PPAR γ 2 and PDX-1 for mice.
Fig. 5 reaches area under blood glucose-time graph over time for mice oral glucose tolerance test blood glucose.
Fig. 6 reaches the percentage ratio that blood glucose reduces over time for blood glucose behind the mouse peritoneal insulin injection.
The specific embodiment
Following embodiment is convenient to understand better the present invention, but does not limit the present invention.Experimental technique among the following embodiment if no special instructions, is conventional method.Used test material among the following embodiment if no special instructions, is to buy from routine biochemistry reagent shop and obtains.
NIH male mice (about 20g) is available from Guangdong Medical Lab Animal Center (SPF level, credit number: the Guangdong word 2005A009 that checks and affirm, SCXK (Guangdong) 2003-0001).SPF level food is available from Guangdong Medical Lab Animal Center.
Glucose, triglyceride (TG), T-CHOL (TC), low density lipoprotein, LDL (LDL-C) and high density lipoprotein (HDL-C) clinical detection reagent box are available from north, Beijing control bio-engineering corporation.The plain ELISA test kit of mouse islets is available from west, Shanghai Tang bio tech ltd.The anti-Mus peroxisome proliferation of rabbit body activated form receptor y 2 (PPAR γ 2), the anti-Mus pancreas duodenum of rabbit homology frame albumen 1 (PDX-1) and the anti-Mus actin of rabbit (actin) are available from Wuhan Boster Biological Technology Co., Ltd..The goat anti-rabbit igg of horseradish peroxidase-labeled is available from Bioisystech Co., Ltd of China fir Golden Bridge in Beijing.Chemiluminescence matrix agent box is available from U.S. KPL company (LotNo.060263).Celluloid marking film is available from the Pall Corporation of Fla..Film for medical X-ray radiography (Kodak China Limited Company, Xiamen, China).The fast fixing powder, developing powder (Guangzhou section skill chemical plant).X ray camera obscura (model: AX-II) available from Shoutou Yuehua Medical Apparatus Factory Co., Ltd..Vertical slab electrophoresis instrument (DYCZ-24DN, Liuyi Instruments Plant, Beijing).Multi-functional microplate reader (GENios, Switzerland TECAN).Tabletop refrigerated centrifuge (HETLICH, the U.S.).Robotics luminesceence analysis system (ULTRA-LUM, the U.S.).Ultraviolet-visible spectrophotometer (JENWAY, Britain).
The preparation of the medicine of embodiment 1, treatment diabetes
(main component is CaSO with the Scorpio crude drug (the municipal rich medical company limited in Shenzhen, lot number 20090314) of 1 mass parts and the Gypsum Fibrosum crude drug of 10 mass parts
42H
2O, Shenzhen Li Feng medicine company limited, lot number 20090118) prepare the medicine (above Chinese crude drug has all reached the corresponding Quality Control examination criteria that 2005 editions Pharmacopoeias of People's Republic of China (an one) are formulated) for the treatment of diabetes, step is as follows:
1,60 ℃ of dryings of Scorpio are 24 hours, pulverize, and cross 100 mesh sieves, get scorpion;
2, the distilled water that adds 5 times of weight in the Gypsum Fibrosum, 95 ℃ of water-baths 1 hour with Cotton Gossypii or filtered through gauze, obtain Gypsum Fibrosum water extract (suspension);
3, scorpion and Gypsum Fibrosum water extract are pressed 1g: the mixed of 50ml, the medicine of the diabetes that obtain medical treatment (Scorpio and Gypsum Fibrosum compound recipe decocting preparation; SG).
The drug effect of the medicine of embodiment 2, treatment diabetes
One, the making of NIH mice diabetes model
NIH male mice (about 20g) fasting is after 24 hours, with 100mg/kg streptozotocin (Streptozotocin, U.S. Sigma company) lumbar injection once (streptozotocin with the fresh preparation of citrate buffer of prior ice bath (0.1M, pH4.5), in 5 minutes, inject finish).After 10 days, the mice of glucostasis rising (blood glucose is more than the 11.1mmol/L) is NIH mice diabetes model.
Two, the administration of NIH mice diabetes model
Administration group first (Scorpio treatment group; D+S): NIH mice diabetes model; The scorpion of the step 1 of embodiment 1; 350mg scorpion/kilogram mice/sky;
Administration group second (Gypsum Fibrosum treatment group; D+G): NIH mice diabetes model; The Gypsum Fibrosum water extract of the step 2 of embodiment 1; 3.5g the water extract of Gypsum Fibrosum/kilogram mice/sky;
Administration group third (Scorpio+Gypsum Fibrosum treatment group; D+SG): NIH mice diabetes model; The medicine of the treatment diabetes of the step 3 of embodiment 1; (water extract with 350mg scorpion and 3.5g Gypsum Fibrosum mixes the medicine that obtains)/kilogram mice/sky;
Positive controls (metformin group; D+M): NIH mice diabetes model; Metformin (Pacific Ocean, Tianjin medical sci-tech group, product batch number 071101); 250mg metformin/kilogram mice/sky;
Normal group (N): normal NIH male mice; DDW;
Diabetes matched group (D): NIH mice diabetes model; DDW;
Normal control group (N+SG): normal NIH male mice; The medicine of the treatment diabetes of the step 3 of embodiment 1; (water extract with 350mg scorpion and 3.5g Gypsum Fibrosum mixes the medicine that obtains)/kilogram mice/sky;
In the above administration group, medicine faces with before being suspended in isopyknic DDW, irritates stomach and gives for 5 weeks, once a day.Blood collecting is a mice on an empty stomach after 6 hours, and blood collecting is preceding 12 hours in addition, stops administration.
Three, drug effect detects
1, body weight, water uptake and food ration
During the administration, periodic monitoring mice body weight, water uptake and food ration.The results are shown in Table 1 before the administration and after 5 weeks of administration.
Body weight, water uptake and food ration before and after the administration of table 1 mice
Data are expressed as mean ± standard deviation (n=10; The mice quantity of n for being used to detect in each processed group); #P＜0.05, ##P＜0.01 is compared with normal group; * P＜0.05, * * P＜0.01 is compared with the diabetes matched group.
With normal group relatively, losing weight has appearred in the diabetes mice in control group, water uptake and food ration significantly increase.Compare with the diabetes matched group, Scorpio+Gypsum Fibrosum treatment group significantly suppresses the reduction of diabetic mice body weight at the dosage of clinical conversion, and minimizing is ingested and taken the photograph water.With diabetes matched group ratio, simple Gypsum Fibrosum treatment group does not obviously influence body weight and food intake dose, but can suppress the increase to water uptake.Compare with the diabetes matched group, simple Scorpio treatment group can suppress the minimizing of body weight, but the absorption of food and water is not significantly influenced.It is suitable with Scorpio+Gypsum Fibrosum treatment group effect that metformin suppresses the diabetes aspect of losing weight, but improve food and the water intake aspect is weaker than Scorpio and gypsum mixtures.
2, Blood Lipid
After 5 weeks of mice administration, the operating instruction of pressing on the test kit detects blood triglyceride, blood T-CHOL, blood low density lipoprotein, LDL and blood hdl level with multi-functional microplate reader at the 492nm place.The results are shown in Table 1 after 5 weeks of administration.
The variation of fasting plasma lipid level after 5 weeks of table 2 mice administration
| ??N | ??N+SG | ??D | ??D+SG | ??D+G | ??D+S | ??D+M | |
| Triglyceride (mmol/L) during the 0th week | ??1.05±0.09 | ??1.03±0.17 | ??0.92±0.12 | ??0.99±0.11 | ??1.09±0.15 | ??1.06±0.07 | ??0.94±0.09 |
| T-CHOL (mmol/L) during the 0th week | ??4.14±0.64 | ??4.10±0.34 | ??3.67±0.41 | ??3.52±0.14 | ??3.47±1.12 | ??3.89±0.37 | ??3.54±0.98 |
| Triglyceride (mmol/L) during the 5th week | ??0.89±0.22 | ??1.02±0.27 | ??1.25±0.21## | ??0.90±0.21** | ??1.38±0.54 | ??1.19±0.23 | ??1.54±0.49 |
| T-CHOL (mmol/L) during the 5th week | ??3.90±0.57 | ??3.82±0.67 | ??4.72±1.74 | ??3.18±0.51* | ??3.82±0.74 | ??3.89±0.54 | ??3.89±0.57 |
| Low-density lipoprotein cholesterol (mmol/L) during the 5th week | ??1.73±0.68 | ??1.69±0.53 | ??1.91±0.48 | ??1.67±0.21 | ??1.91±0.33 | ??2.04±0.34 | ??2.31±0.40 |
| HDL-C (mmol/L) during the 5th week | ??1.28±0.18 | ??1.29±0.19 | ??0.92±0.21## | ??1.03±0.22 | ??1.08±0.27 | ??1.05±0.20 | ??1.08±0.21 |
| T-CHOL/HDL-C during the 5th week | ??3.10±0.61 | ??2.97±0.57 | ??5.21±1.62## | ??3.32±0.88** | ??3.68±1.00* | ??3.79±0.71* | ??3.68±0.63* |
Data are expressed as mean ± standard deviation (n=10; The mice quantity of n for being used to detect in each processed group); #P＜0.05, ##P＜0.01 is compared with normal group; * P＜0.05, * * P＜0.01 is compared with the diabetes matched group.
Blood fat disorder has appearred in the diabetes mice in control group, compares with normal group, and when the 5th week, triglyceride, T-CHOL and ratio (T-CHOL/HDL-C) significantly raise.Compare with the diabetes matched group, Scorpio and gypsum mixtures are in the significantly rising of inhibition blood triglyceride, T-CHOL and T-CHOL/HDL-C ratios of 5 week of administration back.Scorpio and gypsum mixtures are to the not obviously influence of normal animal lipid.Compare with the diabetes matched group, use Gypsum Fibrosum or Scorpio that animal lipid is not all had obviously influence merely, T-CHOL/HDL-C level is but had certain inhibitory action, but be weaker than Scorpio and gypsum mixtures group.Metformin is not obvious to blood fat, and effect is weaker than Scorpio gypsum mixtures group.
3, blood glucose
During the administration, mice carries out blood sugar test (n=10 weekly; The mice quantity of n for being used to detect in each processed group), tested preceding 12 hours, mice stops administration.In addition, part animal (n=5; The mice quantity of n for being used to detect in each processed group) after 5 weeks of administration, in one week of mice drug withdrawal, carry out blood sugar test.Blood sugar test detects on multi-functional microplate reader by the test kit operating instruction.Successive administration in 5 weeks weekly blood sugar test result and drug withdrawal one blood sugar test during week the results are shown in Figure 1.Among Fig. 1, data are expressed as mean ± standard deviation;
AaP＜0.01, " D " compares with " N ";
bP＜0.05, " D+SG " compares with " D ";
cP＜0.05, " D+M " compares with " D ".
Compare with the normal control group, remarkable hyperglycemia appears in the diabetes mice in control group, all keeps a higher level in 6 weeks.Compare with the diabetes contrast, Scorpio and gypsum mixtures are at all remarkable blood sugar lowering of 5 weeks of dosage successive administration of clinical conversion.With the positive drug metformin relatively, Scorpio and gypsum mixtures blood sugar lowering obviously are better than metformin, especially after one week of drug withdrawal, still may command blood glucose is in lower level for Scorpio and gypsum mixtures, and metformin blood glucose has a rebound.Scorpio and Gypsum Fibrosum use the significantly effect of all not finding separately.Scorpio and gypsum mixtures are to the not significantly influence of normal animal blood glucose.
4, serum insulin and pancreatic tissue insulin level
After 5 weeks of mice administration, it is standby to get-80 ℃ of refrigerators of serum placement.Detect serum insulin and pancreatic tissue insulin level, serum insulin and pancreatic tissue insulin all are to measure on microplate reader with the plain ELISA test kit of mouse islets.Mice is 6 hours on an empty stomach before the sampling, and sampling stopped administration in preceding 12 hours.
Fig. 2 A is seen in the variation of mice serum insulin level, and Fig. 2 B is seen in the variation of pancreatic tissue insulin level.Among Fig. 4, data are expressed as mean ± standard deviation (n=5; The mice quantity of n for being used to detect in each processed group);
AaP＜0.01, " D " compares with " N ";
bP＜0.05,
BbP＜0.01, all administration groups are compared with " D ".
Compare with the normal control group, diabetes control group mice serum and pancreatic tissue insulin level occurs and reduce.Compare with the diabetes matched group, Scorpio and gypsum mixtures significantly increase serum insulin and pancreatic tissue insulin level.Metformin also can suppress the reduction of diabetes serum and pancreatic tissue insulin level.Simple Gypsum Fibrosum or Scorpio effect will be weaker than Scorpio and gypsum mixtures.These results suggest Scorpios and gypsum mixtures may promote the islet cells insulin synthesis and promote the effects such as release of insulin.
5, pancreas H﹠amp; E dyeing
After 5 weeks of mice administration, get and do the pathology section after the part pancreas formalin fixed and use.Mice is 6 hours on an empty stomach before the sampling, and sampling stopped administration in preceding 12 hours.The HE coloration result is seen Fig. 3 behind the pancreatic tissue pathological section.
Diabetes control group mice pancreas langerhans obvious atrophy of corpusculum islet cells or disappearance, number obviously reduces.Scorpio and gypsum mixtures significantly promote pancreas langerhans corpusculum islet cell hyperplasia, increase its number.Metformin also has certain effect, but will be weaker than Scorpio+Gypsum Fibrosum treatment group processed group.These results hint that further mice can impel the islet cells of damage to recover, and can promote islet cell hyperplasia.
6, the expression of glycolipid metabolism associated protein
After 5 weeks of mice administration, empty stomach is 6 hours before the sampling, and sampling stopped administration in preceding 12 hours.Get the instantaneous freezing back of part pancreas and place-80 ℃ of standby expression that are used for the glycolipid metabolism associated protein of refrigerator.
Adopt the expression (the anti-anti-Mus PPAR of a rabbit γ 2 and the anti-Mus PDX-1 of rabbit of being respectively) that detects pancreatic tissue PPAR γ 2 and PDX-1, the results are shown in Figure 4.Among Fig. 4, the result of A:PPAR γ 2 and PDX-1 protein expression band; The relative gray density value of B:PPAR γ 2 (deciding normal control is 1, all proofreaies and correct with confidential reference items GAPDH) with PDX-1 protein expression band.Data are expressed as mean ± standard deviation (n=5 among Fig. 4; The mice quantity of n for being used to detect in each processed group);
AaP＜0.01 " D " is compared with " N ";
BbP＜0.01 " D+SG " is compared with " D ";
CcP＜0.01 " D+M " is compared with " D ".
The result of Western blotting shows, Scorpio and gypsum mixtures can promote the expression of PPAR γ 2 and PDX-1, the expression of PPAR γ 2 adjustable PDX-1, and PDX-1 is playing a very important role aspect growth of pancreas islet cells and the insulin gene expression, Scorpio and gypsum mixtures are perhaps by regulating the expression that these proteic variations promote islet cells propagation and insulin gene, thereby insulin level in the raising body, performance diabetes effect.
The carbohydrate tolerance of mice experiment after embodiment 3, the administration
One, oral glucose tolerance
1, the making of NIH mice diabetes model
Two, the administration of NIH mice diabetes model
Scorpio+Gypsum Fibrosum treatment group (D+SG): NIH mice diabetes model; The medicine of the treatment diabetes of the step 3 of embodiment 1; (water extract with 350mg scorpion and 3.5g Gypsum Fibrosum mixes the medicine that obtains)/kilogram mice/sky;
Metformin group (D+M): NIH mice diabetes model; Metformin (Pacific Ocean, Tianjin medical sci-tech group, product batch number 071101); 250mg metformin/kilogram mice/sky;
Normal group (N): normal NIH male mice; DDW;
Diabetes matched group (D): NIH mice diabetes model; DDW;
In the above administration group, medicine faces with before being suspended in isopyknic DDW, irritates stomach and gives for 5 weeks, once a day.
Administration is carried out the experiment of oral glucose tolerance to mice after 5 weeks.Test and stopped administration in preceding 12 hours.After 6 hours, mice is irritated stomach with the glucose of 2.5g/ kilogram, gets blood in 0,0.5,1 and 2 hour tail vein of time point and carries out blood sugar test on an empty stomach, and when getting blood, last bleeding removed, and 2-3 bleeds and gets final product after getting.Blood sugar test is tested on microplate reader with test kit.
In the test of mice oral glucose tolerance, blood glucose is seen Fig. 5 over time.Among Fig. 5, A: mice oral glucose tolerance test blood glucose over time; B: area under blood glucose-time graph; Data are expressed as mean ± standard deviation (n=6; The mice quantity of n for being used to detect in each processed group);
AaP＜0.01, " D " compares with " N ";
bP＜0.05,
BbP＜0.01, " D+SG " compares with " D ";
cP＜0.05, " D+M " compares with " D ".
Compare with normal group, blood glucose significantly raises behind the diabetes mice in control group oral glucose, and area significantly increases under blood glucose-time graph, shows impaired glucose tolerance to occur.Compare with the diabetes matched group, Scorpio and gypsum mixtures significantly suppress the remarkable rising of area under the blood glucose of oral glucose and the blood glucose-time graph.Metformin group and Scorpio+Gypsum Fibrosum treatment group difference is not obvious.
Two, abdominal cavity insulin tolerance
1, the making of NIH mice diabetes model
Two, the administration of NIH mice diabetes model
Scorpio+Gypsum Fibrosum treatment group (D+SG): NIH mice diabetes model; The medicine of the treatment diabetes of the step 3 of embodiment 1; (water extract with 350mg scorpion and 3.5g Gypsum Fibrosum mixes the medicine that obtains)/kilogram mice/sky;
Metformin group (D+M): NIH mice diabetes model; Metformin (Pacific Ocean, Tianjin medical sci-tech group, product batch number 071101); 250mg metformin/kilogram mice/sky;
Normal group (N): normal NIH male mice; DDW;
Diabetes matched group (D): NIH mice diabetes model; DDW;
In the above administration group, medicine faces with before being suspended in isopyknic DDW, irritates stomach and gives for 5 weeks, once a day.
After 5 weeks of administration mice is carried out abdominal cavity insulin tolerance experiment.Test and stopped administration in preceding 12 hours.The short-acting insulin injection comes the U.S. from Novo Nordisk Pharma Inc..After 6 hours, mice is got blood in 0,0.5 and 1 hour tail vein of time point and carries out blood sugar test with the insulin lumbar injection of 0.2U/ kilogram on an empty stomach, and when getting blood, last bleeding removed, and 2-3 bleeds and gets final product after getting.Blood sugar test is tested on microplate reader with test kit.Blood glucose is seen Fig. 6 A over time behind the mouse peritoneal insulin injection, and the percentage ratio that blood glucose reduces is seen Fig. 6 B.Among Fig. 6, data are expressed as mean ± standard deviation (n=6; The mice quantity of n for being used to detect in each processed group);
AaP＜0.01, " D " compares with " N ";
bP＜0.05, " D+SG " compares with " D ";
cP＜0.05, " D+M " compares with " D ".
At 0.5 o'clock, compare with normal control, the percentage ratio of diabetes matched group exogenous insulin blood sugar lowering significantly reduces.Compare with the diabetes matched group, Scorpio and gypsum mixtures significantly increase the hypoglycemic effect of exogenous insulin, and a little less than the metformin effect.This prompting Scorpio and gypsum mixtures can use together with insulin, strengthen its curative effect, reduce its dosage.
Metformin is mainly used in gently, the moderate treatment of diabetes.Show that herein SG also has certain effect for serious diabetes model, and can increase the effect of insulin, effect is better than metformin, and supposition can reduce the clinical consumption of insulin, can use the auxiliary treatment that is used for severe diabetes mellitus with insulin.The mixture of Gypsum Fibrosum and Scorpio does not influence euglycemia, does not therefore have hypoglycemic danger.Because share the preparation of composition, Scorpio and Gypsum Fibrosum can promote insulin function to recover, show new hypoglycemic activity, adding Scorpio in the application of diabetic neuropathy and Gypsum Fibrosum heat clearing away effect etc., thereby the preparation formed of Scorpio and Gypsum Fibrosum particularly has application promise in clinical practice aspect severe diabetes mellitus and the complication treatment thereof in diabetes.
Claims (10)
1. medicine for the treatment of diabetes, its active ingredient is that raw material is made by the Scorpio of 0.5-2 weight portion and the Gypsum Fibrosum of 8-12 weight portion.
2. medicine as claimed in claim 1 is characterized in that: the active ingredient of described medicine is that raw material is made by the Scorpio of 1 weight portion and the Gypsum Fibrosum of 10 weight portions.
3. medicine as claimed in claim 1 or 2 is characterized in that: the active component of described medicine is the mixture of scorpion and Gypsum Fibrosum water extract.
4. medicine as claimed in claim 3 is characterized in that: the preparation method of described Gypsum Fibrosum water extract is: add entry in the Gypsum Fibrosum, 90-100 ℃ water-bath 0.5-3 hour, collect extracting solution, be the Gypsum Fibrosum water extract.
5. medicine as claimed in claim 4 is characterized in that: the preparation method of described scorpion is: with 60 ℃ of dryings of Scorpio 24 hours, pulverize, cross 100 mesh sieves, obtain scorpion; The preparation method of described Gypsum Fibrosum water extract is: add the distilled water of 5 times of weight in the Gypsum Fibrosum, 95 ℃ of water-baths 1 hour are filtered, and obtain the Gypsum Fibrosum water extract.
6. medicine as claimed in claim 5 is characterized in that: the mixture of the active component of described medicine for described scorpion and described Gypsum Fibrosum water extract are obtained by the mixed of 1g: 50ml.
7. as arbitrary described medicine in the claim 1 to 6, it is characterized in that: the dosage form of described medicine is decoction, electuary, powder or pill; Described medicine is soft capsule, granule or oral liquid.
8. the method for preparing the described medicine of claim 1 comprises the steps: the scorpion of 0.5-2 weight portion and the water extract of 8-12 weight portion Gypsum Fibrosum are mixed the medicine of the diabetes that obtain medical treatment.
9. method as claimed in claim 8 is characterized in that: the preparation method of the water extract of described Gypsum Fibrosum is: add entry in the Gypsum Fibrosum, 90-100 ℃ water-bath 0.5-3 hour, collect extracting solution, be the Gypsum Fibrosum water extract.
10. method as claimed in claim 9 is characterized in that: the preparation method of described scorpion is: with 60 ℃ of dryings of Scorpio 24 hours, pulverize, cross 100 mesh sieves, obtain scorpion; The preparation method of described Gypsum Fibrosum water extract is: add the distilled water of 5 times of weight in the Gypsum Fibrosum, 95 ℃ of water-baths 1 hour are filtered, and obtain the Gypsum Fibrosum water extract; Described scorpion and described Gypsum Fibrosum water extract are pressed 1g: the mixed of 50ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102360674A CN101695507B (en) | 2009-10-19 | 2009-10-19 | Medicament for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102360674A CN101695507B (en) | 2009-10-19 | 2009-10-19 | Medicament for treating diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101695507A true CN101695507A (en) | 2010-04-21 |
| CN101695507B CN101695507B (en) | 2011-11-30 |
Family
ID=42140659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102360674A Expired - Fee Related CN101695507B (en) | 2009-10-19 | 2009-10-19 | Medicament for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101695507B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102406661A (en) * | 2010-09-25 | 2012-04-11 | 任步海 | Composite mineral substance crystal for regulating blood fat and blood sugar |
| CN111826433A (en) * | 2019-04-23 | 2020-10-27 | 清华大学深圳研究生院 | Application of LncRNA in diabetes prognosis evaluation and repeated abortion early warning |
-
2009
- 2009-10-19 CN CN2009102360674A patent/CN101695507B/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102406661A (en) * | 2010-09-25 | 2012-04-11 | 任步海 | Composite mineral substance crystal for regulating blood fat and blood sugar |
| CN111826433A (en) * | 2019-04-23 | 2020-10-27 | 清华大学深圳研究生院 | Application of LncRNA in diabetes prognosis evaluation and repeated abortion early warning |
| CN111826433B (en) * | 2019-04-23 | 2023-08-18 | 清华大学深圳研究生院 | Application of LncRNA in prognosis evaluation of diabetes and early warning of recurrent abortion |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101695507B (en) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6896914B2 (en) | Method for normalizing insulin levels | |
| Ishak et al. | Antidiabetic and hypolipidemic activities of Curculigo latifolia fruit: root extract in high fat fed diet and low dose STZ induced diabetic rats | |
| WO2007053134A1 (en) | A method for normalizing insulin levels | |
| EP3132798B1 (en) | Use of composition containing iron (ii) amino acid chelate in preparing drug for regulating and controlling fat metabolism | |
| KR102143990B1 (en) | Formulations for the treatment and prevention of obesity | |
| US20110104290A1 (en) | Compositions for reducing blood glucose level and uses thereof | |
| CN101167802A (en) | Method for preparing cinnamon extraction, cinnamon extraction and its composition and use | |
| JP2011510098A (en) | Pharmaceutical composition for diabetic nephropathy and its preparation and application | |
| Bi et al. | Comparative study of crude and wine-processing Corni Fructus on chemical composition and antidiabetic effects | |
| CN101695507B (en) | Medicament for treating diabetes | |
| CN114246918A (en) | Traditional Chinese medicine composition for treating hashimoto thyroiditis and preparation method thereof | |
| CN1565467B (en) | Use of cornel and its extract in preparation alpha-glucosidase inhibitor medicine | |
| CN108578419B (en) | A kind of hypoglycemic medicine composition of ginsenoside Rg1 and melbine | |
| CN101474346B (en) | Longstamen onion bulb extract as well as preparation method and application thereof | |
| US20190365827A1 (en) | Composition for treating diabetic disease | |
| WO2013138964A1 (en) | Application of iso-daphnetin compound in preparation of anti-diabetic medicines | |
| CN101147749A (en) | Divaricate velvetplant medicinal preparation for treating diabetes | |
| CN108314620A (en) | Different sequence chinese tallow tree element i and j and its pharmaceutical composition and its application | |
| CN103285113B (en) | Pharmaceutical composition for preventing and/or treating diabetes mellitus | |
| KR100473530B1 (en) | Composition containing an extract of sopungsungi-won crude drug complex for preventing and treating diabetes mellitus | |
| KR20100111088A (en) | Composition for preventing and treating diabetes mellitus or diabetic complications comprising extract of herbal combination | |
| CN109966283A (en) | Application of the degreasing cinnamon polyphenol extract in preparation prevention and treatment diabetic nephropathy product | |
| CN112675186B (en) | Pharmaceutical composition and application thereof | |
| CN104740345B (en) | Treat Chinese medicine composition of diabetes and preparation method thereof | |
| KR102265793B1 (en) | Health functional food composition containing extract of Antirrhinum majus L. as an active ingredient for lowering blood glucose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111130 Termination date: 20211019 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |